3D Systems Corporation, in collaboration with French MedTech company TISSIUM, has achieved a significant milestone with the FDA's De Novo marketing authorization for their innovative 3D-printed medical device aimed at regenerative repair of peripheral nerve damage. This first-of-its-kind, bioabsorbable device, known as COAPTIUM® CONNECT with TISSIUM Light, leverages TISSIUM's proprietary biomorphic programmable polymers and 3D Systems' advanced bioprinting technologies. The approval marks a transformative step in patient care, offering a sutureless, atraumatic solution for nerve repair. This achievement underscores the partnership's success in pioneering regenerative medical solutions and sets a new industry standard for high-resolution elastomeric medical implants.